A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TORTUGA
  • Sponsors Galapagos NV
  • Most Recent Events

    • 04 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top